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To understand the epidemiology of multidrug-resistant
(MDR) Acinetobacter baumannii and define individual risk
factors for multidrug resistance, we used epidemiologic
methods, performed organism typing by pulsed-field gel
electrophoresis (PFGE), and conducted a matched case-
control retrospective study. We investigated 118 patients,
on 27 wards in Israel, in whom MDR A. baumannii was iso-
lated from clinical cultures. Each case-patient had a control
without MDR A. baumannii and was matched for hospital
length of stay, ward, and calendar time. The epidemiologic
investigation found small clusters of up to 6 patients each
with no common identified source. Ten different PFGE
clones were found, of which 2 dominated. The PFGE pat-
tern differed within temporospatial clusters, and antimicro-
bial drug susceptibility patterns varied within and between
clones. Multivariate analysis identified the following signifi-
cant risk factors: male sex, cardiovascular disease, having
undergone mechanical ventilation, and having been treated
with antimicrobial drugs (particularly metronidazole).
Penicillins were protective. The complex epidemiology may
explain why the emergence of MDR A. baumannii is difficult
to control. 
A
cinetobacter baumannii has emerged as an important
nosocomial pathogen (1–5). Hospital outbreaks have
been described from various geographic areas (6–9), and
this organism has become endemic in some of them. The
role of the environmental contamination in the transmis-
sion of nosocomial infections in general and in A. bau-
mannii infections in particular is well recognized (10,11).
A. baumannii does not have fastidious growth require-
ments and is able to grow at various temperatures and pH
conditions (12). The versatile organism exploits a variety
of both carbon and energy sources. These properties
explain the ability of Acinetobacter species to persist in
either moist or dry conditions in the hospital environment,
thereby contributing to transmission (13,14). This hardi-
ness, combined with its intrinsic resistance to many
antimicrobial agents, contributes to the organism’s fitness
and enables it to spread in the hospital setting. 
The nosocomial epidemiology of this organism is com-
plex. Villegas and Hartstein reviewed Acinetobacter out-
breaks occurring from 1977 to 2000 and hypothesized that
endemicity, increasing rate, and increasing or new resist-
ance to antimicrobial drugs in a collection of isolates sug-
gest transmission. These authors suggested that
transmission should be confirmed by using a discriminato-
ry genotyping test (15). The importance of genotyping
tests is illustrated by outbreaks that were shown by classic
epidemiologic methods and were thought to be caused by
a single isolate transmitted between patients; however,
when molecular typing of the organisms was performed, a
more complex situation of multiple unrelated strains caus-
ing the increasing rates of infections by A. baumannii was
discovered (16–18). 
Almost 25 years ago, researchers observed acquired
resistance of A. baumannii to antimicrobial drugs com-
monly used at that time, among them aminopenicillins,
ureidopenicillins, first  and second-generation cephalo-
sporins, cephamycins, most aminoglycosides, chloram-
phenicol, and tetracyclines (19). Since then, strains of A.
baumannii have also gained resistance to newly developed
antimicrobial drugs. Although multidrug-resistant (MDR)
A. baumannii is rarely found in community isolates, it
became prevalent in many hospitals (20). MDR A. bau-
mannii has recently been established as a leading nosoco-
mial pathogen in several Israeli hospitals, including our
institution (21,22). Several locally contained small out-
breaks of MDR A. baumannii occurred in our institution
during the late 1990s. In 1999, however, the incidence of
MDR A. baumannii isolation had doubled compared to the
previous 2 years, and the organism became endemic in
many wards (unpub. data). 
The likelihood of isolation of A. baumannii from a hos-
pitalized patient is related to temporospatial (extrinsic,
ecologic characteristics) factors such as colonization
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*Tel Aviv Sourasky Medical Center, Tel Aviv, Israelpressure (23), nurse-to-patient ratio, and other ward char-
acteristics and to individual patient risk factors (character-
istics). The current study was designed to examine the
occurrence and spread of A. baumannii within our institu-
tion, as well as to define individual risk factors for isola-
tion of this organism. 
Methods
Hospital Setting, Data Collection, 
and Microbiologic Testing 
This study was performed at the Tel-Aviv Sourasky
Medical Center, Israel, a 1,200–bed tertiary care teaching
hospital with 70,000 admissions annually. Approximately
82,500 clinical microbiologic cultures are processed annu-
ally. We designed this as a matched case-control study to
identify the individual risk factors for having MDR A. bau-
mannii. We also performed epidemiologic investigations
and genetic typing of the organisms to clarify the spread of
this nosocomial pathogen. 
Case-patients were defined as patients from whom
MDR A. baumannii was isolated from any clinical culture
(not surveillance cultures) during a 6-month period, from
January 1, 2001, to June 30, 2001. A control patient was
matched to each study patient on temporospatial factors as
previously described (24). Briefly, controls were randomly
chosen from the list of patients who stayed on the same
ward in the same calendar month as the matched case-
patient and who were hospitalized for at least the same
number of days by the day the culture yielded MDR A.
baumannii in the study patient. Controls were not MDR A.
baumannii positive (i.e., the patient’s samples were cul-
tured, and either non-MDR A. baumannii or no A. bau-
mannii was isolated, or the patient’s samples were never
cultured). Random control selection was performed by cre-
ating a list of all possible controls, assigning each candi-
date a random number, and choosing the highest random
number (without replacement).
Case-patients and control patients were included only
once in the study. Data were collected from the patients’
records and from hospital computerized databases into a
pre-prepared electronic questionnaire (Microsoft Access,
Microsoft Corp., Redmond, WA, USA). The parameters
registered for each patient (case-patients and controls)
were age, sex, habits of smoking and alcohol consumption
before hospitalization, cause and ward of hospitalization,
transfer from another institution or ward within our insti-
tution, intensive care unit (ICU) stay, underlying disorders,
immunosuppressive therapy, severity of illness as defined
by the McCabe score (25), functional capacity and neuro-
logic condition at time of isolation of A. baumannii, Foley
catheter, invasive devices, surgery, mechanical ventilation,
dialysis, infection, and antimicrobial drug therapy. Only
variables occurring before inclusion in the study (culture
day for case-patients and match day for controls) were ana-
lyzed as possible risk factors. A. baumannii was isolated
from clinical specimens submitted to the microbiology
laboratory and identified by using the Gram-Negative
Identification Panel (Microscan, Dade Behring Inc.,
Sacramento, CA, USA). This system may not distinguish
between closely related genotypic strains of Acinetobacter,
and thus, some of these organisms may belong to these
closely related strains. Susceptibilities were determined by
automated microdilution broth testing (Neg/Urine Combo
panel, Dade Behring Inc.). Resistance to imipenem and
meropenem was confirmed by using Kirby-Bauer disk dif-
fusion, according to the National Council for Clinical
Laboratory Standards (NCCLS) guidelines. A. baumannii
isolates were collected prospectively and stored at –70°C
for further work-up. 
Analysis of Chromosomal DNA
by Pulsed-Field Gel Electrophoresis (PFGE)
Isolates of our patients, when available, were kept
frozen at –70ºC and genetically characterized with PFGE.
DNApreparation and cleavage with 20 U of ApaI endonu-
clease (New England Biolabs, Beverly, MA, USA) were
preformed as previously described (26). Electrophoresis
was performed in a 1% agarose gel (BMA products) pre-
pared and run in 0.5 x Tris-borate-EDTA buffer on a
CHEF-DR III apparatus (Bio-Rad Laboratories, Hercules,
CA, USA). The initial switch time was 5 s, the final switch
time was 35 s, and the run time was 23 h at 6 V/cm. Gels
were stained in ethidium bromide, destained in distilled
water, and photographed by using a Bio-Rad GelDoc 2000
camera. DNApatterns were analyzed visually and by using
Diversity software (Bio-Rad). PFGE DNA patterns were
compared and interpreted according to the criteria of
Tenover et al. (27). The obtained PFGE DNA patterns
were used to cluster the clones of the A. baumannii clini-
cal isolates that were included in the study. 
Definitions
We defined A. baumannii as MDR when the organism
was resistant to all studied agents (including
piperacillin/tazobactam, cefepime, ceftazidime, aztreon-
am, ciprofloxacin, gentamicin, tobramycin), but we
allowed susceptibility to amikacin, ampicillin-sulbactam,
imipenem, meropenem, and minocycline. Infection was
defined according to the Centers for Disease Control and
Prevention guidelines and modified to include community-
acquired infections and to exclude asymptomatic bacteri-
uria (28).
Standard criteria were used to define underlying disor-
ders. Disease was considered to be active if signs of dis-
ease were clinically apparent or if the patient received
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receiving immunosuppressive therapy if he had undergone
chemotherapy within 3 weeks, if he had been treated with
>20 mg of prednisone daily for >2 weeks before entering
the study, or if he had recently received antirejection drugs
or other immunosuppressive therapy.
Severity of illness due to comorbidities was defined
according to the McCabe score (25). Functional capacity
during the index hospitalization was divided into 3 cate-
gories: independent, needing help for activities of daily
living, and bedridden. Renal failure was defined as a crea-
tinine level >2 mg/dL. Neurologic function was catego-
rized according to 3 conditions: full consciousness,
confusional state or dementia, and unconscious. 
For each patient included in the study, we noted
whether a susceptible A. baumannii was isolated in any
culture before isolation of the MDR strain. We noted the
number of antimicrobial drugs that the patient received
between the time of admission until inclusion in the study,
and we recorded home antimicrobial drug therapy sepa-
rately. Recent hospitalization was defined as hospital stay
within 3 months of the index hospitalization. We noted any
surgical procedure, mechanical ventilation, and invasive
procedure that took place 1 month before the patient’s
inclusion in the study.
Statistical Analysis
Statistics were run in Stata version 7 (Stata Corp.,
College Station, TX). All analyses were matched to corre-
spond to the study design. All variables were examined by
univariate analysis with the McNemar test and paired
Student t test. Variables with a p value <0.2 in the univari-
ate analysis were included in the multivariate model. Risk
factors were examined by using conditional logistic
regression. A final model was built that included all the
variables with a p value <0.2. Variables that were not
retained in the model by this procedure were then tested
for confounding by adding them 1 at a time to the model
and examining their effects on the β coefficients. Variables
which caused substantial confounding (change in β coeffi-
cient of >10%) were included in the final model. After con-
structing the explanatory model, the effect of exposure to
antimicrobial agents (i.e., antimicrobial treatment before
inclusion in the study) was examined by adding them to
the model.
In addition to examining statistical significance and
confounding, the effect modification between variables
was evaluated by testing appropriate interaction terms for
statistical significance. Colinearity was examined by
replacing variables with each other and examining the
effect on the model. All statistical tests were 2-tailed. A p
value <0.05 was considered significant.
Results
From January 1, 2001, to June 30, 2001, we identified
133 patients with a clinical culture of MDR A. baumannii.
Four patients were not hospitalized in our institution (i.e.,
they were hospitalized elsewhere) and were excluded from
the study. Charts were available for 120 case-patients, but
no controls could be matched for 2 of them. Thus, 236
patients were included in the study (118 case-patients and
their matched controls). Sites from which A. baumannii
was initially isolated included respiratory tract 38 (32%),
wounds 23 (19.5%), urine 22 (19%), blood 19 (16%), and
sterile fluids and catheter tips 16 (13.5%).
Epidemiology and PFGE Typing
Among the 118 case-patients, the first MDR A. bau-
mannii in 104 (88%) was isolated after more than 72 h of
hospitalization (mean 17.5 ± 23.7 days). Among the other
14 case-patients, 12 were admitted from another institution
or had been hospitalized recently. No nosocomial origin
was documented in 2 cases. A. baumannii was initially iso-
lated in 27 different wards. Figure 1 shows the case distri-
bution among them. Ahigher concentration of patients was
clearly evident in 3 wards: the general ICU (ward “I”, 16
cases), and two internal medicine wards (ward Q, 10 cases,
and ward W, 9 cases). 
The time distribution of new cases is presented in
Figure 2. We did not find any aggregate of cases within a
specific ward at any specific time. The occurrence during
the months February, May, and June was lower than dur-
ing January, March, and April. This circumstance is not
explained by differences in infection control measures rec-
ommended; during the entire study period this included
contact isolation of every patient from whom MDR A.
baumannii was isolated and cohorting of case-patients if
single patient rooms were not available. A statement was
added to the culture result: “MDR organism; contact
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Figure 1. Distribution of case-patients according to ward.isolation is required.” Epidemiologic nurses checked with
the ward to confirm that the patient was isolated. On cer-
tain floors, surveillance (nose, forearms, armpits, and
perirectal swabs) and environmental cultures (using swabs,
contact plates, and direct culturing of fluids) were per-
formed to try to identify a reservoir of organism. In this
study, case-patients and controls were matched by ward
and calendar time to focus on individual risk factors and
not on differences between wards and temporal changes.
Atotal of 51 unique patient MDR strains were available
for further study, and they were analyzed by using PFGE.
We identified 10 distinct clones of A. baumannii. Figure 3
shows 6 different PFGE-defined clones, each having from
1 to 4 subtypes showing a 1- to 2-band difference. Two of
the 10 different clones dominated: 22 case-patients had
clone Aand 10 case-patients had clone B, although no spe-
cific clone dominated in a specific ward but rather each
clone was spread among several wards during the entire
study period (Table 1). We also found various antimicro-
bial drug susceptibility phenotypes (all belonging to our
definition of MDR) within each PFGE clone, but almost
all cases of carbapenem resistance belonged to clone A. 
Individual Risk Factors
The study patients’ characteristics are displayed in
Table 2. Case-patients were similar to their matched con-
trol patients with respect to mean age (67.7 vs 64.4 years)
and sex distribution (men, n = 71 [60%] vs controls, n = 59
[50%]). The groups were also similar in habits of smoking
and alcohol consumption and in the occurrence of coexist-
ing conditions of lung disease, diabetes, kidney, liver dis-
ease, malignancy, and posttransplantation condition. The
groups differed in the prevalence of ischemic heart dis-
ease: study case-patients 69% vs. controls 52% (OR 2.33,
p = 0.006). 
Hospital events (before study entry) differed between
case-patients and controls. Case-patients were more likely
to have received mechanical ventilation (OR 2.9,
p = 0.001), to be treated with metronidazole (OR 1.9,
p = 0.038), and to have a Foley catheter (OR 2.42, p =
0.005). They were less likely to have had another bedside
surgical procedure before the isolation of A. baumannii
(OR 0.53, p = 0.035). 
Several variables tended to be more associated with
case-patients, but the values did not reach statistical sig-
nificance: admission from another institute (OR 2.1, p =
0.06), unconsciousness (OR 0.706, p = 0.07), and previous
use of third-generation cephalosporin (OR 1.63, p = 0.093)
and of macrolides (OR 2.25, p = 0.056). A matched multi-
variate model, adjusted for the hospital length of stay, was
developed by using conditional logistic regression
(Table 3). The variables that were identified by this model
as being significant risk factors for MDR A. baumannii
were male sex (OR 3.8, p = 0.002), ischemic heart disease
(OR 3.3, p = 0.005), mechanical ventilation (OR 6.2, p <
0.001), and home antimicrobial drug use (OR 4.7, p =
0.018). Two agents used in the hospital were associated
with MDR A. baumannii: metronidazole was identified as
a risk factor (OR 2.3, p = 0.018), and the penicillin group
was identified as having a protective effect (OR = 0.38,
p = 0.029).
Discussion
We sought to understand the epidemiology of MDR A.
baumannii and to define the individual risk factors for
acquiring this infectious agent. Our findings illustrated its
complex epidemiology and delineated individual risk fac-
tors. The complex epidemiology may explain the difficul-
ties encountered in controlling the emergence of this
nosocomial pathogen.
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Figure 2. Monthly case distribution, 2001
Figure 3. A typical pulsed-field gel electrophoresis analysis of
selected isolates of Adnetobacter baumannii restricted with ApaI.
Lane 1 shows λ ladder used as molecular size marker. Lanes
11–13 are of strains not included in the trial. The gel shows 6 dif-
ferent clones of A. baumannii: 5 isolates belong to clone A and 2
belong to clone B (the 2 dominant clones). Single isolates belong-
ing to clones C, D, E, and F can be seen.Almost all cases of MDR A. baumannii in our study
were hospital acquired: 88% were acquired in our institu-
tion during the index hospitalization, and 10% were
imported into the hospital by patients with recent exposure
to the healthcare system. The MDR A. baumannii strains
isolated in our institution belonged to multiple PFGE
clones: 50% of the isolates that were typed belonged to 2
dominant clones, and the other, nondominant clones
caused few cases each. 
Clones did not cluster in place (i.e., hospital location)
or in time. Moreover, when an increase in incidence was
observed in a certain ward, the increase was not associat-
ed with a single clone, and up to 4 different clones were
present concomitantly in a ward. We also found antimi-
crobial susceptibility profile variation within clones and
similarities between clones, which showed that suscepti-
bility pattern was not a useful marker for clonality.
Carbapenem resistance occurred in 75% of the isolates
belonging to 1 of the 2 dominant clones (clone A) but was
rare among other clones. This finding illustrates well the
complexity of the epidemiology of this nosocomial
pathogen. Even with molecular typing data, determining
the modes of spread of this organism was difficult, partly
because we did not have a complete collection of the iso-
lates. Despite our expending extensive effort, we were
unable to determine the source of these resistant strains.
Although we believe that patient-to-patient transmission
through contaminated hands of healthcare workers and
fomites is the main route by which these MDR organisms
spread, the combined epidemiologic and molecular data
did not directly support this hypothesis. The lack of evi-
dence for patient-to-patient spread in our study may be
related to transferring patients between wards and the
presence of a substantial number of undetected carriers
(the “submerged iceberg phenomenon”) who spread the
bacteria. Alternative explanations, such as repeated entry
(import) of the same clone to the hospital ecosystem at
various times and locations (e.g., from an disease-endem-
ic institution or contaminated supply or food) must be
considered as well.
The individual risk factors for isolation of MDR A.
baumannii that were identified by the multivariate analysis
were male sex, underlying comorbidity of ischemic heart
disease, mechanical ventilation, and antimicrobial drug
treatment. The finding of male sex and of ischemic heart
disease being risk factors for carriage of and infection with
resistant gram-negative bacilli had also been observed by
our group, as well as by others for carriage of extended
spectrum  β-lactamase (ESBL) producing Entero-
bacteriaceae and Pseudomonas aeruginosa (29–31). We
hypothesize that these associations may be related to the
following factors: 1) patient-to-patient transmission within
multipatient rooms (patients who are segregated by sex
and need for intensive monitoring); 2) use of certain
nonantimicrobial medication, such as calcium channel
blockers, which may predispose for adherence or invasive-
ness by affecting the host or the pathogens (32,33); and 3)
hormonal or other sex differences which may predispose a
person for colonization and infection. These hypotheses
are currently being studied in our facilities. The multivari-
ate analysis did not identify admission from another insti-
tution as a significant risk factor. This probably relates to
the small number (and proportion) of patients admitted
from other institutions who were identified to be carriers of
MDR  A. baumannii. These few patients may, however,
have played an important role to the entrance of new
clones and the spread of the organisms within our institu-
tion. Moreover, case-patients that are not detected may still
be important in the spread of these organisms. Overall, we
believe that the identified risk factors represent both sever-
ity of the patient’s condition, use of invasive devices, and
effect on the normal flora, all of which promote MDR A.
baumannii colonization, growth, and invasiveness. 
The administration of penicillin had a protective effect
against isolation of MDR A. baumannii. This protective
effect was significant after confounding by multivariate
analysis was controlled for. Penicillins lack activity against
these MDR strains, and the protective effect cannot relate
to sulbactam, since a sulbactam combination is seldom
used in our institution. To the best of our knowledge, such
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cillins may possibly cause specific changes in the
microflora that oppose colonization and growth of
Acinetobacter spp., but the validity of this observation
awaits further research. As for many other resistant organ-
isms, metronidazole was a significant risk factor for MDR
A. baumannii, likely because of its effects on the competi-
tive normal intestinal flora. The observation that carbapen-
em resistance was much more frequent in the dominant
clone could suggest that this phenotype may have con-
tributed to the evolutionary success of the clone. 
A previous study clearly demonstrated that the epi-
demiology and risk factors may vary for different clones
(17). This finding may lead to a dilution of effects and
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we did not analyze clone-specific risk factors because we
did not believe that we truly had an epidemic clone and
because the number of patients affected by each clone was
too small to allow a statistically significant comparison.
Temporospatial factors, although they undoubtedly
have an important role in the spread of resistant organisms,
were not within the scope of this study. We controlled for
these factors by the study design, i.e., matching by hospi-
tal location, length of stay before inclusion in the study,
and calendar time. Confounding may, however, have been
introduced to our study by factors for which we did not
control, such as residing in a multipatient room next to a
patient with MDR A. baumannii. 
We used risk set sampling (by matching for time at risk)
but did not allow case-patients to be eligible to be controls
before becoming cases. Since no clustering in time and
place occurred, and controls were chosen from 35,000
admitted patients, this method of sampling should not have
yielded biased results.
Despite the large number of cases that we identified, we
were unable to understand the mode of spread and the rea-
son for emergence of these organisms in our institution.
This fact may be because only some of the isolates were
available for typing or because of the complex mode of
spread in our hospital. Further study will be required to
more fully understand the intricate phenomenon of MDR
A. baumannii spread.
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